API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will fund ongoing clinical development of IDE196 (darovasertib), a protein kinase C (PKC) inhibitor, and crizotinib, as combination therapy in metastatic uveal melanoma, including our Phase 2/3 potential registrational clinical trial.
Lead Product(s): Darovasertib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $143.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 27, 2023
Details:
The net proceeds will fund ongoing clinical development of IDE196 (darovasertib), a protein kinase C (PKC) inhibitor, and crizotinib, as combination therapy in metastatic uveal melanoma, including our Phase 2/3 potential registrational clinical trial.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 24, 2023
Details:
IDE196 (darovasertib) is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. Currently being developed in combination with Crizotinib for metastatic cutaneous melanoma.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
IDE196 (darovasertib) is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. Currently being developed for metastatic uveal melanoma.
Lead Product(s): Darovasertib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
Under the collaboration, Pfizer will support evaluation of IDE196 (darovasertib) and crizotinib combination therapy in the IDEAYA's planned Phase 2/3 clinical trial in Metastatic Uveal Melanoma and to continue support of the company's ongoing Phase 2 clinical trial in MUM.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration May 16, 2023
Details:
IDE196 (darovasertib) is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. Currently being developed for metastatic uveal melanoma.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
IDE196 (darovasertib), a PKC inhibitor, is a clinical stage development compound for patients with tumors harboring GNAQ or GNA11 mutations, including in metastatic uveal melanoma (MUM) and skin melanoma.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
Darovasertib (IDE196) is a potent, selective small molecule inhibitor of protein kinase C (PKC). Mutations in GNAQ or GNA11 (GNAQ/11) have been identified in approximately 90% of patients with metastatic UM.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
Under the agreement, the company will support evaluation of darovasertib and crizotinib combination therapy in Phase 2 potential registration-enabling clinical trial in patients with metastatic uveal melanoma and in Phase 1 clinical trial in patients with cMET-driven tumors.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 14, 2022
Details:
Darovasertib and binimetinib combination reports 2 partial responses (PR), including one confirmed partial response, out of nine evaluable patients with at least 2 post-baseline scans (22%) in MUM; 1 PR patient (-40.5%) is awaiting a confirmatory scan.
Lead Product(s): Darovasertib,Binimetinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
Details:
The clinical combination of IDE196 and crizotinib is being evaluated by IDEAYA in collaboration with Pfizer pursuant to a clinical trial collaboration and supply agreement.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
The study will evaluate IDE196 and crizotinib combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including metastatic uveal melanoma (MUM), skin melanoma, lung cancer and colorectal cancer.
Lead Product(s): Darovasertib,Crizotinib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ideaya Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 24, 2020
Details:
IDEAYA has met the clinical protocol criteria for cohort expansion in the cutaneous melanoma cohort of its Phase 2 basket arm evaluating IDE196 monotherapy in solid tumors harboring GNAQ or GNA11 hotspot mutations (GNAQ/11).
Lead Product(s): Darovasertib
Therapeutic Area: Oncology Product Name: IDE196
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
IDE196 is a potent and selective protein kinase C (PKC) inhibitor being evaluated in an ongoing Phase 1/2 tumor-agnostic clinical trial in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) hotspot mutations.
Lead Product(s): Darovasertib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
IDEAYA and Pfizer will form a Joint Development Committee (JDC), and there will be joint decision making and data sharing of the clinical trial results between the parties.
Lead Product(s): Darovasertib,Binimetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ideaya Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 18, 2020
Details:
53 patients enrolled in Phase 1/2 monotherapy study, including 49 in MUM and 4 in Cutaneous Melanoma, from earlier-reported 40 patients in December 2019.
Lead Product(s): Darovasertib,Binimetinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
Details:
Preclinical studies will test IDE196, in vitro, to determine whether endothelial cells with GNAQ mutations can recover normal cell function as well as in vivo pharmacological inhibition of PKC.
Lead Product(s): Darovasertib
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2020